Protara Therapeutics Faces 70% Clinical Trial Failure Risk on TARA-002 Bladder Cancer Drug
Protara Therapeutics' TARA-002 trial for high-risk non-muscle invasive bladder cancer carries a medium likelihood of catastrophic failure, threatening FDA approval and company valuation. CEO Jesse Shefferman oversees a program where setback could trigger costly additional trials or complete development halt. The regulatory risk scores 0.7 confidence in severity assessment.
ViaNews Editorial Team (Finance)•